Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Fri, 20.06.2025
Formycon AG
Press Release // June 20, 2025
Formycon bond 2025/2029: Public subscription now also possible via Deutsche Börse
The subscription period via Deutsche Börse AG's DirectPlace is now open and will close on 30 June 2025 at 12:00 p.m. CEST (subject to early closure)
The unsecured senior bond has a target volume of €50 million and carries a variable i [ … ]
Wed, 18.06.2025
Formycon AG
Press Release // June 18, 2025
Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities
Management provides detailed report on financial year 2024 and provides outlook for 2025
Supervisory Board expands to six members; Klaus Röhrig re-elected
Dr. Graham Keith Dixon elected as a new member of the Sup [ … ]
Wed, 18.06.2025
Formycon AG
Press Release // June 18, 2025
Formycon AG: Subscription period for 2025/2029 corporate bond has started
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that the securities prospectus for the newly issued corporate bond 2025/2029 (ISIN NO0013586024 / WKN A4DFJH) has been approved by the Luxembourg finan [ … ]
Tue, 17.06.2025
Formycon AG
Press Release // June 17, 2025
Formycon plans public corporate bond issuance to support next growth phase within attractive Biosimilar markets
Unsecured bond 2025/2029 with a target volume of EUR 50 million and variable interest rate
Proceeds will support the targeted development of biosimilar product portfolio and the execution of the next grow [ … ]
Thu, 05.06.2025
Formycon AG
Press Release // June 5, 2025
Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil
Raniviso® becomes first approved Lucentis® biosimilar in Brazil
Commercialization partnership established with Brazilian pharmaceutical company Biomm
Product launch in Brazil expected in Q4 2025, kicking off the commercial rollout of FYB201 [ … ]
Tue, 27.05.2025
Formycon AG
Press Release // May 27, 2025
Formycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar, in Canada
FYB202/Otulfi™ is now commercially available in Canada in both subcutaneous and intravenous formulations
Launch expands market presence beyond the U.S. and Europe, offering broader treatment [ … ]
Mon, 19.05.2025
Formycon AG
Press Release // May 19, 2025
Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated F [ … ]
Mon, 12.05.2025
Formycon AG
Press Release // May 12, 2025
Formycon reports strong operational performance and financial results for first quarter of 2025
Strong operational start to the year with market approvals for FYB203 (Aflibercept) in Europe and the United Kingdom as well as new commercialization partnerships with Teva and Lotus
Encouraging market launch of FYB202/Ot [ … ]
Wed, 07.05.2025
Formycon AG
Presse Release // May 7, 2025Formycon invites to conference call on the results of the first quarter of 2025 and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management [ … ]
Thu, 27.03.2025
Formycon AG
Press Release // March 27, 2025
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)
Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil [ … ]